Basel, 1 February 2017 – Lonza Group AG (“Lonza”, VTX: LONN.VX) has successfully placed 5.0 million new shares by way of an accelerated bookbuilding procedure with selected investors in Switzerland (private placement) and outside of Switzerland to institutional investors and qualified institutional buyers (in reliance on Regulation S and 144A of the U.S. Securities Act) (the “Placement”).
The shares were placed at CHF 173.00 per new share and the gross proceeds from the Placement amount are equal to CHF 865 million. The net proceeds from the capital increase are intended to be used to partially finance the contemplated acquisition of Capsugel S.A., which was announced in December 2016. The shares placed are sourced from authorized capital of Lonza.
Additionally, Lonza has entered into lock up undertakings ending on the later of (1) 180 days following the first day of trading of the new shares issued in the Placement and (2) if the additional equity issuance proceeds, as referenced in Lonza’s announcement of the Capsugel acquisition on 15 December 2016, 90 days following the first day of trading of the shares issued in that equity issuance. Such lock up undertakings are subject to customary exceptions and waiver by the joint bookrunners, and also exclude the underwritten equity issuance referred to above, which will be reduced by the gross proceeds raised in this accelerated bookbuilding.
The new shares are expected to be listed and admitted to trading on the SIX Swiss Exchange on 3. February 2017. Payment and settlement is expected to take place on the same date.
To download the complete press release follow this link: www.thefuturelonza.com/abb (country restrictions may apply)
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
